Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. PBA
3. ALAR
4. CCH:LN
5. META
6. CCHGY
7. PRY:IM
8. PRYMY
9. SPY
10. SKA-B

Go back to Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016

Anavex Life Sciences (AVXL) 31-Week Data Shows Anavex 2-73 Continues to be Well Tolerated - FBR

July 25, 2016 8:47 AM EDT

FBR Capital analyst Christopher James reiterated an Outperform rating and $10 price target on Anavex Life Sciences (NASDAQ: AVXL) after the company presented the first of two posters on a Part-B extension of its Phase IIa Study with Anavex 2-73 in Alzheimer's Disease at the Alzheimer's Association International Conference... More